Moogene Medi Co., Ltd. (XKON:322970)

Market Cap	23.52B
Revenue (ttm)	12.95M
Net Income (ttm)	-2.08B
Shares Out	10.05M
EPS (ttm)	-332.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,196
Average Volume	1,972
Open	2,160.00
Previous Close	2,160.00
Day's Range	2,100.00 - 2,390.00
52-Week Range	1,410.00 - 3,090.00
Beta	0.09
RSI	69.93
Earnings Date	n/a

About Moogene Medi

Moogene Medi Co., Ltd. develops gene therapies based on its proprietary gene-editing platform technology. The company’s product portfolio comprises MG-001, which is in Phase I clinical trials to treat colon cancer; MG-002 that is in preclinical stage for use in the treatment of pancreatic cancer; and MG-003, which is in preclinical stage for use in the treatment of diabetes mellitus. Its research stage products include MG-004 for treating hair loss and MG-005 for use in the treatment of Crohn's disease. The company was founded in 2016 and is ba...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 322970

Financial Performance

In 2019, Moogene Medi's revenue was 12.95 million, a decrease of -87.17% compared to the previous year's 100.95 million. Losses were -2.08 billion, 41.4% more than in 2018.